Evidence map›Paper›PMID 41192481›Full record

ArticleJournal of lipid research2025

Sphingomyelin regulates astrocyte activity by regulating NF-κB signaling via HDAC1/3 expression.

Ryo Kadowaki, Hana Hirose, Gai Takimoto, Takafumi Kohama, Hiroyuki Nakamura

Abstract read
In one paragraph

Article in Journal of lipid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Iranian journal of pharmaceutical research : IJPR
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ryo KadowakiLaboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba, Japan.
Hana HiroseLaboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba, Japan.
Gai TakimotoLaboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba, Japan.
Takafumi KohamaLaboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba, Japan.
Hiroyuki NakamuraLaboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba, Japan. Electronic address: nakahiro@faculty.chiba-u.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astrocytes comprise approximately 40% of CNS cells and have pivotal roles in brain functions. Under steady-state conditions, astrocytes maintain homeostasis in the CNS through the uptake or release of neurotransmitters. However, in neurodegenerative conditions, astrocytes are activated by inflammatory cytokines, such as interleukin-1alpha (IL-1α) and TNF-α, which are released from activated microglia. Activated astrocytes release several inflammatory cytokines and neurotoxic substances, resulting in neuronal injury. Sphingolipids are a series of bioactive lipids involved in several biological processes, such as apoptosis, inflammatory response, cell cycle, and immune response. SM is a sphingolipid that is a major component of the cellular membrane and is also involved in inflammatory responses. We report that SM promotes IL-1α/TNF-α-induced expressions of representative astrocyte mRNAs and astrocyte activation through the NF-κB pathway. In contrast, reduction of SM by knockdown of sphingomyelin synthase 1 (SMS1) and/or SMS2 suppresses astrocyte activation. Furthermore, removal of SM by the blockade of ceramide transfer protein suppresses astrocyte activation via the induction of histone deacetylase (HDAC) 1 and HDAC3; subsequently, the levels of acetylated p65 (Lys 310) are reduced, leading to the suppression of the NF-κB pathway. Our findings further the understanding of the regulation of astrocyte activation by sphingolipids.

Indexed as

AstrocytesHistone Deacetylase 1Histone DeacetylasesNF-kappa BSignal TransductionSphingomyelinsAnimalsHistone Deacetylase 3Interleukin-1alphaMembrane ProteinsMiceTransferases (Other Substituted Phosphate Groups)Tumor Necrosis Factor-alphaHistone Deacetylase 1Histone Deacetylase 3Histone DeacetylasesInterleukin-1alphaMembrane ProteinsNF-kappa BSphingomyelinsTransferases (Other Substituted Phosphate Groups)Tumor Necrosis Factor-alphaabnormal astrocyte activationhistone deacetylaseneurodegenerative diseasesNF-κB signalingp65 acetylationsphingomyelin

Identifiers

PMID41192481
PMCPMC12721041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.